{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:05:46Z","timestamp":1792044346686,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11102-025-01510-7","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:13:03Z","timestamp":1741162383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dopamine agonists and weight changes in prolactinoma patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Nicholas","family":"Contento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Edward","family":"Vates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Brehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-5053","authenticated-orcid":false,"given":"Ismat","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"05","key":"1510_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1055\/s-0029-1211245","volume":"101","author":"D Sautner","year":"1993","unstructured":"Sautner D, Saeger W, L\u00fcdecke DW (1993) Tumors of the Sellar region mimicking pituitary adenomas. Exp Clin Endocrinol Diabetes 101(05):283\u2013289","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"1510_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/beem.1999.0036","volume":"13","author":"RN Clayton","year":"1999","unstructured":"Clayton RN (1999) Sporadic pituitary tumours: from epidemiology to use of databases. Best Pract Res Clin Endocrinol Metab 13(3):451\u2013460","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"1510_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","volume":"23","author":"A Colao","year":"2009","unstructured":"Colao A (2009) The prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575\u2013596","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"1510_CR4","first-page":"3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro-and macroprolactinomas in men. J Clin Endocrinol Metabolism 85(9):3053\u20133057","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1510_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"Mindermann T, Wilson CB (1994) Age-related and gender\u2010related occurrence of pituitary adenomas. Clin Endocrinol 41(3):359\u2013364","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1510_CR6","first-page":"841","volume":"28","author":"M Vaneckova","year":"2007","unstructured":"Vaneckova M, Seidl Z, Hana V, Jarkovska Z (2007) Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology. Neuroendocrinol Lett 28(6):841\u2013845","journal-title":"Neuroendocrinol Lett"},{"issue":"12","key":"1510_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJM199103213241207","volume":"324","author":"A Klibanski","year":"1991","unstructured":"Klibanski A, Zervas NT (1991) Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med 324(12):822\u2013831","journal-title":"N Engl J Med"},{"issue":"5","key":"1510_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R, Bronstein MD (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Investig 31(5):436\u2013444","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"1510_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/13543784.11.6.787","volume":"11","author":"A Colao","year":"2002","unstructured":"Colao A, Somma CD, Lombardi G, Pivonello R, Sarno AD (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11(6):787\u2013800","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"1510_CR10","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Colao A (2001) Resistance to Cabergoline as compared with Bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metabolism 86(11):5256\u20135261","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"5","key":"1510_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485\u2013534","journal-title":"Endocr Rev"},{"issue":"4","key":"1510_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-08-0611","volume":"159","author":"M Kars","year":"2008","unstructured":"Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159(4):363","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1510_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","volume":"48","author":"Y Greenman","year":"1998","unstructured":"Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 48(5):547\u2013553","journal-title":"Clin Endocrinol"},{"key":"1510_CR14","doi-asserted-by":"crossref","unstructured":"Goede DL, Hauser RS (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss medical weekly, 136(1516)","DOI":"10.4414\/smw.2006.10955"},{"issue":"4","key":"1510_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.eprac.2020.09.001","volume":"27","author":"F Al Sabie","year":"2021","unstructured":"Al Sabie F, Tariq Z, Erickson D, Donegan D (2021) Association between prolactinoma and body mass index. Endocr Pract 27(4):312\u2013317","journal-title":"Endocr Pract"},{"issue":"1","key":"1510_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.7243\/2053-3640-1-2","volume":"1","author":"JFS Pereira-Lima","year":"2013","unstructured":"Pereira-Lima JFS, Le\u00e3es CGS, Neto FMF, Barbosa MV, Silva AL, Oliveira MD (2013) Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia. Res J Endocrinol Metab 1(1):2","journal-title":"Res J Endocrinol Metab"},{"issue":"1","key":"1510_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with Bromocriptine. Eur J Endocrinol 147(1):77\u201384","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1510_CR18","first-page":"72","volume":"16","author":"A Southon","year":"2003","unstructured":"Southon A, Walder K, Sanigorski AM, Zimmet P, Nicholson GC, Kotowicz MA, Collier G (2003) The Taq IA and Ser311 Cys polymorphisms in the dopamine D2 receptor gene and obesity. Diabetes Nutr Metab 16(1):72\u201376","journal-title":"Diabetes Nutr Metab"},{"issue":"3","key":"1510_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11102-013-0496-y","volume":"17","author":"AP Athanasoulia","year":"2014","unstructured":"Athanasoulia AP, Sievers C, Uhr M, Ising M, Stalla GK, Schneider HJ (2014) The effect of the ANKK1\/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas. Pituitary 17(3):240\u2013245","journal-title":"Pituitary"},{"key":"1510_CR20","doi-asserted-by":"publisher","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","volume":"13","author":"R Pirchio","year":"2022","unstructured":"Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS (2022) Metabolic effects of prolactin. Front Endocrinol 13:1015520","journal-title":"Front Endocrinol"},{"key":"1510_CR21","doi-asserted-by":"publisher","first-page":"1002320","DOI":"10.3389\/fendo.2022.1002320","volume":"13","author":"P Kirsch","year":"2022","unstructured":"Kirsch P, Kunadia J, Shah S, Agrawal N (2022) Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol 13:1002320","journal-title":"Front Endocrinol"},{"key":"1510_CR22","doi-asserted-by":"publisher","first-page":"935872","DOI":"10.3389\/fcdhc.2023.935872","volume":"4","author":"HY Chien","year":"2023","unstructured":"Chien HY, Chen SM, Li WC (2023) Dopamine receptor agonists mechanism of actions on glucose Lowering and their connections with prolactin actions. Front Clin Diabetes Healthc 4:935872","journal-title":"Front Clin Diabetes Healthc"},{"issue":"3","key":"1510_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.aace.2021.01.004","volume":"7","author":"M Ali","year":"2021","unstructured":"Ali M, Mirza L (2021) Morbid obesity due to prolactinoma and significant weight loss after dopamine agonist treatment. AACE Clin Case Rep 7(3):204\u2013206","journal-title":"AACE Clin Case Rep"},{"issue":"3","key":"1510_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","volume":"14","author":"K Berinder","year":"2011","unstructured":"Berinder K, Nystr\u00f6m T, H\u00f6ybye C, Hall K, Hulting AL (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14(3):199\u2013207","journal-title":"Pituitary"},{"issue":"1","key":"1510_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-015-0094-4","volume":"7","author":"NA Pala","year":"2015","unstructured":"Pala NA, Laway BA, Misgar RA, Dar RA (2015) Metabolic abnormalities in patients with prolactinoma: response to treatment with Cabergoline. Diabetol Metab Syndr 7(1):1\u20136","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"1510_CR26","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1530\/EC-19-0286","volume":"8","author":"S Byberg","year":"2019","unstructured":"Byberg S, Futtrup J, Andreassen M, Krogh J (2019) Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connections 8(10):1395\u20131404","journal-title":"Endocr Connections"},{"issue":"4","key":"1510_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM Santos-Silva","year":"2011","unstructured":"Santos-Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 19(4):800\u2013805","journal-title":"Obesity"},{"issue":"4","key":"1510_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1463-1326.2011.01534.x","volume":"14","author":"CD Gibson","year":"2012","unstructured":"Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of Cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metabolism 14(4):335\u2013340","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"1510_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/sj.ijo.0802492","volume":"28","author":"H Soran","year":"2004","unstructured":"Soran H, Wilding J, MacFarlane I (2004) Body weight and prolactinoma: a retrospective study. Int J Obes 28(1):183\u2013183","journal-title":"Int J Obes"},{"issue":"4","key":"1510_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1046\/j.1365-2265.2002.01510.x","volume":"56","author":"R Yermus","year":"2002","unstructured":"Yermus R, Ezzat S (2002) Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol 56(4):562\u2013562","journal-title":"Clin Endocrinol"},{"issue":"2","key":"1510_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1365-2265.1999.00700.x","volume":"50","author":"E Delgrange","year":"1999","unstructured":"Delgrange E, Donckier J, Maiter D (1999) Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol 50(2):271","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1510_CR32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22(6):724\u2013763","journal-title":"Endocr Rev"},{"key":"1510_CR33","doi-asserted-by":"crossref","unstructured":"Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W,\u2026 Fowler,JS (2001). Brain dopamine and obesity. The Lancet, 357(9253), 354\u2013357.","DOI":"10.1016\/S0140-6736(00)03643-6"},{"issue":"2","key":"1510_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","volume":"12","author":"A Shibli-Rahhal","year":"2009","unstructured":"Shibli-Rahhal A, Schlechte J (2009) The effects of hyperprolactinemia on bone and fat. Pituitary 12(2):96\u2013104","journal-title":"Pituitary"},{"issue":"1","key":"1510_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000054522","volume":"71","author":"KG Bina","year":"2000","unstructured":"Bina KG, Cincotta AH (2000) Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in Ob\/ob mice. Neuroendocrinology 71(1):68\u201378","journal-title":"Neuroendocrinology"},{"issue":"23","key":"1510_CR36","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/0024-3205(89)90066-0","volume":"45","author":"AH Cincotta","year":"1989","unstructured":"Cincotta AH, Meier AH (1989) Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by Bromocriptine treatment. Life Sci 45(23):2247\u20132254","journal-title":"Life Sci"},{"key":"1510_CR37","doi-asserted-by":"crossref","unstructured":"Folgueira, C., Beiroa, D., Porteiro, B., Duquenne, M., Puighermanal, E., Fondevila,M. F.,\u2026 Nogueiras, R. (2019). Hypothalamic dopamine signalling regulates brown fat thermogenesis. Nature metabolism, 1(8), 811\u2013829.","DOI":"10.1038\/s42255-019-0099-7"},{"issue":"4","key":"1510_CR38","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1210\/jc.2002-021137","volume":"88","author":"C Ling","year":"2003","unstructured":"Ling C, Svensson L, Od\u00e9n B, Weijdeg\u00e5rd B, Ed\u00e9n B, Ed\u00e9n S, Billig H (2003) Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metabolism 88(4):1804\u20131808","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"4","key":"1510_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1530\/acta.0.1250392","volume":"125","author":"LB Creemers","year":"1991","unstructured":"Creemers LB, Zelissen PMJ, Van\u2019t Verlaat JW, Koppeschaar HPF (1991) Prolactinoma and body weight: a retrospective study. Eur J Endocrinol 125(4):392\u2013396","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1510_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ijo.2013.216","volume":"38","author":"A Vlassopoulos","year":"2014","unstructured":"Vlassopoulos A, Combet E, Lean ME (2014) Changing distributions of body size and adiposity with age. Int J Obes 38(6):857\u2013864","journal-title":"Int J Obes"},{"issue":"16","key":"1510_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJM197810192991602","volume":"299","author":"JN Carter","year":"1978","unstructured":"Carter JN, Tyson JE, Tous G, Van Vliet S, Faiman C, Friesen HG (1978) Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 299(16):847\u2013852","journal-title":"N Engl J Med"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01510-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:45:46Z","timestamp":1746521146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01510-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01510-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"22 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}